Med-tech financings totaled $6.08 billion in the first two months of 2026, slightly below the $6.31 billion raised in January to February 2025, a year-over-year decline of about 4%. Even so, the early 2026 total remains well above the openings seen in 2020 ($5.61 billion), 2022 ($4.36 billion), 2023 ($1.67 billion) and 2024 ($4.66 billion).
Amid rising demand for its Neuromark system, Neurent Medical Ltd. opened a new manufacturing facility in Ireland, which will serve as the central hub for the production of the device which treats chronic rhinitis.
Months after revealing a U.S. FDA nod for the Rhinaer Stylus to treat chronic rhinitis, Aerin Medical Inc. reported the closing of a $48 million equity financing. In addition, the company revealed that Matt Brokaw, who has deep experience in the ear, nose and throat (ENT) space, has come on board as president and CEO.
Aerin Medical Inc., an Austin, Texas-based company focused on minimally invasive solutions for chronic nasal conditions, has won U.S. FDA clearance for the Rhinaer Stylus to treat chronic rhinitis. The Rhinaer procedure can be performed under a local anesthetic in an ear, nose and throat (ENT) physician’s office, with no incisions and minimal discomfort.
